​FDA Approvals

 

 

Use of Immunotherapeutic Expanded to Bladder Cancer11913The U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for six types of cancer.2/8/2017 6:54:03 PM583https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1702007_bladder_150x190_1.jpg" style="BORDER&#58;0px solid;" />Use of Immunotherapeutic Expanded to Bladder CancerThe U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for six types of cancer.33
Molecularly Targeted Therapeutic Approved for Another Type of Non-Hodgkin Lymphoma11926The U.S. Food and Drug Administration action means ibrutinib is now an approved treatment for three types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.2/8/2017 7:01:49 PM586https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1702006_Lymphoma_150x190_1.jpg" width="177" style="BORDER&#58;0px solid;" />Molecularly Targeted Therapeutic Approved for Another Type of Non-Hodgkin LymphomaThe U.S. Food and Drug Administration action means ibrutinib is now an approved treatment for three types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.34
New Molecularly Targeted Therapeutic Approved for Ovarian Cancer1900The newly approved therapeutic is for treating women whose cancers test positive for BRCA1 and BRCA2 mutations with a new genetic test.1/25/2017 7:41:03 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1612058_Ovarian_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Molecularly Targeted Therapeutic Approved for Ovarian CancerThe newly approved therapeutic is for treating women whose cancers test positive for BRCA1 and BRCA2 mutations with a new genetic test.32
Immunotherapeutic Use Expanded to Head and Neck Cancer3808The U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for five types of cancer.11/17/2016 3:18:31 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1611023_Immunothera_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Head and Neck CancerThe U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for five types of cancer.31
FDA Approves New Treatment for Soft Tissue Sarcoma3795Adding the newly approved therapeutic to standard treatment improved survival for patients with advanced disease.10/26/2016 3:13:23 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1610080_FndSoftTissue_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />FDA Approves New Treatment for Soft Tissue SarcomaAdding the newly approved therapeutic to standard treatment improved survival for patients with advanced disease.30
New Immunotherapy Option for Treating Metastatic Lung Cancer3813The U.S. Food and Drug Administration approval means there are now three immunotherapeutics called checkpoint inhibitors approved for treating lung cancer10/25/2016 2:30:54 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/Science%20Stories/1610066_FDA_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Immunotherapy Option for Treating Metastatic Lung CancerThe U.S. Food and Drug Administration approval means there are now three immunotherapeutics called checkpoint inhibitors approved for treating lung cancer29
Immunotherapeutic Use Expanded to Include Head and Neck Cancer3810The U.S. Food and Drug Administration approval provides a new treatment option for patients with the most common type of head and neck cancer9/26/2016 2:31:52 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/pembrolizumab_HandNCancers_Approval-150x190.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Include Head and Neck CancerThe U.S. Food and Drug Administration approval provides a new treatment option for patients with the most common type of head and neck cancer28
Liquid Biopsy Approved for Lung Cancer3815The FDA-approved diagnostic test uses blood samples to look for specific mutations in certain patients with metastatic lung cancer.9/26/2016 1:50:23 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1606050_lung_150x190_1.jpg" width="177" style="BORDER&#58;0px solid;" />Liquid Biopsy Approved for Lung CancerThe FDA-approved diagnostic test uses blood samples to look for specific mutations in certain patients with metastatic lung cancer. 27
New Immunotherapeutic Approved for Bladder Cancer3805The approval provides the first new treatment option in more than 30 years for patients with the most common type of bladder cancer6/9/2016 6:50:27 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/Bladder_urothelial_carcinoma_150x190.jpg" style="BORDER&#58;0px solid;" />New Immunotherapeutic Approved for Bladder CancerThe approval provides the first new treatment option in more than 30 years for patients with the most common type of bladder cancer26
Immunotherapeutic Use Expanded to Hodgkin Lymphoma3811The U.S. Food and Drug Administration approval provides a new option for patients with the most common type of Hodgkin lymphoma6/9/2016 6:01:38 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/Nivo_HodgkinLymphomaThumb_150x190.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Hodgkin LymphomaThe U.S. Food and Drug Administration approval provides a new option for patients with the most common type of Hodgkin lymphoma25

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300